You have probably had a blood test and been told your results are "normal". But what does normal mean when the reference ranges were built on population averages that include millions of people already on a trajectory toward metabolic disease? Conventional markers are necessary, but they are not sufficient. Here is what they miss, and what emerging epigenomic measures can add.
The conventional panel and its blind spots
A standard metabolic blood panel typically includes fasting glucose, HbA1c, a lipid profile (total cholesterol, LDL, HDL, triglycerides), and liver enzymes. These markers are well-validated and cheap. Their limitation is timing: most only become abnormal once metabolic dysfunction is already well established.
- HbA1c reflects average glucose over 8-12 weeks; it misses transient post-meal spikes that drive vascular damage.
- Fasting glucose can remain normal for years while post-load insulin resistance progresses silently.
- Standard LDL-C does not distinguish between large buoyant particles (lower risk) and small dense LDL (higher risk).
- Liver enzymes (ALT, AST) only rise once significant hepatocellular damage has already occurred.
Advanced markers worth knowing
Fasting insulin and HOMA-IR
Measuring insulin alongside glucose allows calculation of HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), a far earlier marker of metabolic dysfunction than glucose alone. Published HOMA-IR cutoffs for insulin resistance commonly fall in the ~1.9–2.5 range depending on population, assay, and study design - so a single hard threshold should be interpreted cautiously, and ideally alongside clinical context. Elevated HOMA-IR can flag insulin resistance years before HbA1c crosses the prediabetes threshold.
Triglyceride-to-HDL ratio
The triglyceride-to-HDL ratio is a useful proxy for insulin resistance and small dense LDL particle predominance, both of which carry independent cardiovascular risk - but cutoffs are not universal. In the ADDITION-Leicester cohort of white Europeans, optimal cutoffs were roughly 2.0 mg/dL (0.9 mmol/L) for women and 3.8 mg/dL (1.7 mmol/L) for men; other populations and reviews often cite general estimates around 2.5–3.0 mg/dL, with further variation by ethnicity.1 This simple calculation from a standard lipid panel is consistently underused in clinical practice.
Adiponectin
Adiponectin is an insulin-sensitising hormone secreted by adipose tissue. Low levels, which occur paradoxically as fat mass increases, independently predict type 2 diabetes and cardiovascular events. Importantly, adiponectin gene expression is epigenetically regulated: hypermethylation of the ADIPOQ promoter suppresses output in obesity, providing a molecular link between fat accumulation and insulin resistance.2
A "normal" result on a standard panel is not the same as metabolically healthy. The absence of disease is not the presence of resilience.
Where epigenomics fits
DNA methylation patterns at specific CpG sites, particularly ABCG1, TXNIP, and PPARGC1A, have been prospectively associated with type 2 diabetes in large cohort studies.3 In that nested case-control analysis, differential methylation at these loci was linked to incident diabetes over a mean of 8.5 years of follow-up - offering an earlier molecular signal than many conventional biomarkers alone.
Unlike a blood test result, a methylation profile also responds to intervention, allowing clinicians to track whether a patient's lifestyle programme is producing real biological change, not just improvements on paper.
A practical framework
For anyone serious about understanding their metabolic health, a sensible baseline assessment combines:
- Standard panel: fasting glucose, HbA1c, full lipid profile, liver enzymes, eGFR.
- Insulin resistance: fasting insulin, HOMA-IR, triglyceride-to-HDL ratio.
- Inflammation: high-sensitivity CRP, IL-6 (where available).
- Epigenomic: targeted methylation panel covering validated metabolic CpG loci.
This combination captures what conventional medicine currently measures, what it tends to miss, and what epigenomics can reveal about trajectory and reversibility. Together, they build a picture detailed enough to act on before the crisis arrives.
References
- Mostafa SA, et al. The association of the triglyceride-to-HDL cholesterol ratio with insulin resistance in white European and South Asian men and women. PLoS One. 2012.
- Kim AY, et al. Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance. Nat Commun. 2015.
- Chambers JC, et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes. Lancet Diabetes Endocrinol. 2015.
Your voice matters in the story of health.
Feel free to share your opinion in the comments below.
